1
|
Maluleke T, Benecke R, Oladejo S, Feulner G, Kern S, Lister J, McClelland G, Njoki M, Noack P, Petruccione F, Rajaratnam K, Waitt C, Rosenkranz B, Pillai G. Cross-disciplinary mathematical modelling to benefit healthcare - could clinical pharmacology play an enabling role? Br J Clin Pharmacol 2024; 90:2509-2516. [PMID: 39082394 DOI: 10.1111/bcp.16192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 07/01/2024] [Accepted: 07/03/2024] [Indexed: 09/28/2024] Open
Abstract
Clinical pharmacology is often the nexus in any cross-disciplinary team that is seeking solutions for human healthcare issues. The use and application of real-world data and artificial intelligence to better understand our ecosystem has influenced our view at the world and how we do things. This has resulted in remarkable advancements in the healthcare space and development of personalized medicines with great attributes from the application of models and simulations, contributing to a more efficient healthcare development process. A cross-disciplinary symposium was held in December 2023, whereby experts from different scientific disciplines engaged in a high-level discussion on the opportunities and challenges of mathematical models in different fields, possible future developments and decision making. A strong interlink amongst the disciplines represented was apparent, with clinical pharmacology identified as the one which integrates various scientific disciplines. Deliberate and strategic cross-disciplinary dialogues are required to break out of the silos and implement integration for efficiency and cost-effectiveness of novel interventions.
Collapse
Affiliation(s)
- Tirhani Maluleke
- F. Hoffmann La-Roche, Johannesburg, South Africa
- Fundisa African Academy of Medicines Development, Cape Town, South Africa
| | - Rohan Benecke
- Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Sunday Oladejo
- School for Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
| | - Georg Feulner
- Potsdam Institute for Climate Impact Research, Member of the Leibniz Association, Potsdam, Germany
| | - Steve Kern
- Global Health Labs, Bellevue, Bellevue, Washington, USA
| | | | | | - Miriam Njoki
- Science For Africa (SFA) Foundation, Nairobi, Kenya
| | - Patrick Noack
- University of Applied Sciences, Weihenstephan-Triesdorf, Germany
| | - Francesco Petruccione
- School for Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
- National Institute for Theoretical and Computational Sciences (NITheCS), Stellenbosch, South Africa
| | - Kanshukan Rajaratnam
- School for Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
| | - Catriona Waitt
- Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
- Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
| | - Bernd Rosenkranz
- Fundisa African Academy of Medicines Development, Cape Town, South Africa
- Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- Institute for Clinical Pharmacology and Toxicology, Charité Universitätsmedizin, Berlin, Germany
| | - Goonaseela Pillai
- CP+ Associates GmbH, Basel, Switzerland
- Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa
- Pharmacometrics Africa NPC, Cape Town, South Africa
| |
Collapse
|
2
|
Fischer AE, Abrahams M, Shankland L, Lalla-Edward ST, Edward VA, De Wit J. The evolution of HIV self-testing and the introduction of digital interventions to improve HIV self-testing. FRONTIERS IN REPRODUCTIVE HEALTH 2023; 5:1121478. [PMID: 36864847 PMCID: PMC9971956 DOI: 10.3389/frph.2023.1121478] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Accepted: 01/12/2023] [Indexed: 02/16/2023] Open
Abstract
HIV self-testing (HIVST) complements traditional HIV testing programmes by removing barriers and increasing access to testing for key populations, and digital interventions have been developed for HIVST to improve the testing and linkage to care experience for users. The first HIVST kit was proposed in 1986, but it took 10 years for the home sample collection (HSC) HIVST to become available and another 16 years for rapid diagnostic test HIVST to be approved by the Federal Drug Administration. Since then, studies have shown high usability and performance of HIVST, which led the World Health Organization formally recommending HIVST in 2016, and currently almost 100 countries have incorporated HIVST into their national testing strategy. Despite the popularity, HIVST present challenges around pre-and post-test counselling, as well as the ability to report results and link users to care, and digital interventions for HIVST have been introduced to address these challenges. The first digital intervention for HIVST was introduced in 2014 and showed that digital interventions could be used to distribute HIVST kits, report results and link users to care. Since then, dozens of studies have been conducted, which have validated and expanded on these early findings, but many were pilot studies with small sample sizes and lacked the standardization of indicators required to aggregate data across platforms to prove impact at scale. For digital interventions for HIVST to be championed for scale-up, they must continue to show measurable impact at larger scales, while still maintaining and standardizing data security and integrity.
Collapse
Affiliation(s)
- Alex Emilio Fischer
- Aviro Health, Cape Town, South Africa
- Department of Interdisciplinary Social Science, Public Health, Utrecht University, Utrecht, Netherlands
| | | | | | | | - Vinodh A. Edward
- Department of Interdisciplinary Social Science, Public Health, Utrecht University, Utrecht, Netherlands
- The Aurum Institute, Johannesburg, South Africa
- School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
| | - John De Wit
- Department of Interdisciplinary Social Science, Public Health, Utrecht University, Utrecht, Netherlands
| |
Collapse
|
3
|
Tagoe ET, Nonvignon J, van Der Meer R, Megiddo I, Godman B. Challenges to the delivery of clinical diabetes services in Ghana created by the COVID-19 pandemic. J Health Serv Res Policy 2023; 28:58-65. [PMID: 35786026 PMCID: PMC9253720 DOI: 10.1177/13558196221111708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
OBJECTIVE The barriers to delivering clinical non-communicable disease services in low- and middle-income countries have risen with the onset of COVID-19. Using Ghana as a case study, this article examines the changes COVID-19 has brought to diabetes service delivery and considers policy responses to deal with future such outbreaks. METHODS We conducted 18 interviews between November 2020 and February 2021 with health professionals and administrators from primary, secondary and tertiary facilities within the Ghana Health Service. The analysis was performed using deductive and inductive methods. RESULTS There were six general themes in interviewees' responses: (1) COVID-19 had exacerbated the problems of high medicine and service costs and medicine shortages, (2) the pandemic had exacerbated problems of poor patient record keeping, (3) COVID-19 had reduced the availability of suitably trained health providers, (4) staff had become demoralized by management's unwillingness to make innovative changes to cope with the pandemic, (5) COVID-19 led to a reorganization of diabetes services, and (6) the country's national health insurance scheme lacked flexibility in dealing with the pandemic. CONCLUSIONS Access to resources is limited in LMICs. However, our study highlights practical policy responses that can improve health providers' response to COVID-19 and future pandemics.
Collapse
Affiliation(s)
- Eunice Twumwaa Tagoe
- Eunice Twumwaa Tagoe, Management Science,
University of Strathclyde, 16 Richmond Street, Glasgow, SL G1 1XQ, UK.
| | | | | | | | | |
Collapse
|
4
|
Ngangue-Siewe IN, Ndjeunia-Mbiakop P, Kala-Chouakeu NA, Bamou R, Talipouo A, Djamouko-Djonkam L, Vontas J, Mavridis K, Tombi J, Tchuinkam T, Mbida-Mbida JA, Antonio-Nkondjio C. Bendiocarb and Malathion Resistance in Two Major Malaria Vector Populations in Cameroon Is Associated with High Frequency of the G119S Mutation (Ace-1) and Overexpression of Detoxification Genes. Pathogens 2022; 11:pathogens11080824. [PMID: 35894047 PMCID: PMC9330212 DOI: 10.3390/pathogens11080824] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 07/19/2022] [Accepted: 07/21/2022] [Indexed: 12/10/2022] Open
Abstract
The spread of pyrethroid resistance in malaria vectors is a major threat affecting the performance of current control measures. However, there is still not enough information on the resistance profile of mosquitoes to carbamates and organophosphates which could be used as alternatives. The present study assessed the resistance profile of Anopheles gambiae s.l. to bendiocarb and malathion, at the phenotypic and molecular levels, in different eco-epidemiological settings in Cameroon. Anopheles gambiae s.l. mosquitoes were collected from four eco-epidemiological settings across the country and their susceptibility level to bendiocarb and malathion was determined using WHO tubes bioassays. The ace-1 target site G119S mutation was screened by PCR. Reverse Transcription quantitative PCR 3-plex TaqMan assays were used to quantify the level of expression of eight genes associated with metabolic resistance. Resistance to malathion and/or bendiocarb was recorded in all study sites except in mosquitoes collected in Kaélé and Njombé. The Ace-1 (G119S) mutation was detected in high frequencies (>40%) in Kékem and Santchou. Both An. gambiae and An. coluzzii were detected carrying this mutation. The cytochrome P450s gene Cyp6p3 associated with carbamate resistance and the glutathione S-transferase gene Gste2 associated with organophosphate resistance were found to be overexpressed. Genes associated with pyrethroid (Cyp6m2, Cyp9k1, Cyp6p3) and organochlorine (Gste2, Cyp6z1, Cyp6m2) and cuticle resistance (Cyp4g16) were also overexpressed. The rapid spread of resistance to organophosphates and carbamates could seriously compromise future control strategies based on IRS. It is therefore becoming important to assess the magnitude of bendiocarb and malathion resistance countrywide.
Collapse
Affiliation(s)
- Idriss Nasser Ngangue-Siewe
- Laboratory of Animal Biology and Physiology, University of Douala, Douala P.O. Box 24157, Cameroon; (I.N.N.-S.); (J.A.M.-M.)
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale (OCEAC), Yaoundé P.O. Box 288, Cameroon; (P.N.-M.); (N.A.K.-C.); (R.B.); (A.T.); (L.D.-D.)
| | - Paulette Ndjeunia-Mbiakop
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale (OCEAC), Yaoundé P.O. Box 288, Cameroon; (P.N.-M.); (N.A.K.-C.); (R.B.); (A.T.); (L.D.-D.)
- Faculty of Sciences, University of Yaoundé I, Yaoundé P.O. Box 812, Cameroon;
| | - Nelly Armanda Kala-Chouakeu
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale (OCEAC), Yaoundé P.O. Box 288, Cameroon; (P.N.-M.); (N.A.K.-C.); (R.B.); (A.T.); (L.D.-D.)
- Vector-Borne Diseases Laboratory of the Applied Biology and Ecology Research Unit (VBID-URBEA), Department of Animal Biology, Faculty of Science of the University of Dschang, Dschang P.O. Box 067, Cameroon;
| | - Roland Bamou
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale (OCEAC), Yaoundé P.O. Box 288, Cameroon; (P.N.-M.); (N.A.K.-C.); (R.B.); (A.T.); (L.D.-D.)
- Vector-Borne Diseases Laboratory of the Applied Biology and Ecology Research Unit (VBID-URBEA), Department of Animal Biology, Faculty of Science of the University of Dschang, Dschang P.O. Box 067, Cameroon;
| | - Abdou Talipouo
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale (OCEAC), Yaoundé P.O. Box 288, Cameroon; (P.N.-M.); (N.A.K.-C.); (R.B.); (A.T.); (L.D.-D.)
- Faculty of Sciences, University of Yaoundé I, Yaoundé P.O. Box 812, Cameroon;
| | - Landre Djamouko-Djonkam
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale (OCEAC), Yaoundé P.O. Box 288, Cameroon; (P.N.-M.); (N.A.K.-C.); (R.B.); (A.T.); (L.D.-D.)
- Vector-Borne Diseases Laboratory of the Applied Biology and Ecology Research Unit (VBID-URBEA), Department of Animal Biology, Faculty of Science of the University of Dschang, Dschang P.O. Box 067, Cameroon;
| | - John Vontas
- Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, 70013 Heraklion, Greece; (J.V.); (K.M.)
- Pesticide Science Laboratory, Department of Crop Science, Agricultural University of Athens, 11855 Athens, Greece
| | - Konstantinos Mavridis
- Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, 70013 Heraklion, Greece; (J.V.); (K.M.)
| | - Jeannette Tombi
- Faculty of Sciences, University of Yaoundé I, Yaoundé P.O. Box 812, Cameroon;
| | - Timoléon Tchuinkam
- Vector-Borne Diseases Laboratory of the Applied Biology and Ecology Research Unit (VBID-URBEA), Department of Animal Biology, Faculty of Science of the University of Dschang, Dschang P.O. Box 067, Cameroon;
| | - Jean Arthur Mbida-Mbida
- Laboratory of Animal Biology and Physiology, University of Douala, Douala P.O. Box 24157, Cameroon; (I.N.N.-S.); (J.A.M.-M.)
| | - Christophe Antonio-Nkondjio
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale (OCEAC), Yaoundé P.O. Box 288, Cameroon; (P.N.-M.); (N.A.K.-C.); (R.B.); (A.T.); (L.D.-D.)
- Vector Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
- Correspondence: ; Tel.: +237-699-53-86-56
| |
Collapse
|
5
|
Tchouakui M, Assatse T, Mugenzi LMJ, Menze BD, Nguiffo-Nguete D, Tchapga W, Kayondo J, Watsenga F, Manzambi EZ, Osae M, Wondji CS. Comparative study of the effect of solvents on the efficacy of neonicotinoid insecticides against malaria vector populations across Africa. Infect Dis Poverty 2022; 11:35. [PMID: 35462556 PMCID: PMC9036736 DOI: 10.1186/s40249-022-00962-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Accepted: 03/15/2022] [Indexed: 11/26/2022] Open
Abstract
Background New insecticides with a novel mode of action such as neonicotinoids have recently been recommended for public health by WHO. Resistance monitoring of such novel insecticides requires a robust protocol to monitor the development of resistance in natural populations. In this study, we comparatively used three different solvents to assess the susceptibility of malaria vectors to neonicotinoids across Africa. Methods Mosquitoes were collected from May to July 2021 from three agricultural settings in Cameroon (Njombe-Penja, Nkolondom, and Mangoum), the Democratic Republic of Congo (Ndjili-Brasserie), Ghana (Obuasi), and Uganda (Mayuge). Using the CDC bottle test, we compared the effect of three different solvents (ethanol, acetone, MERO) on the efficacy of neonicotinoids against Anopheles gambiae s.l. In addition, TaqMan assays were used to genotype key pyrethroid-resistant markers in An. gambiae and odds ratio based on Fisher exact test were used to evaluate potential cross-resistance between pyrethroids and clothianidin. Results Lower mortality was observed when using absolute ethanol or acetone alone as solvent for clothianidin (11.4‒51.9% mortality in Nkolondom, 31.7‒48.2% in Mangoum, 34.6‒56.1% in Mayuge, 39.4‒45.6% in Obuasi, 83.7‒89.3% in Congo and 71.1‒95.9% in Njombe pendja) compared to acetone + MERO for which 100% mortality were observed for all the populations. Similar observations were done for imidacloprid and acetamiprid. Synergist assays (PBO, DEM and DEF) with clothianidin revealed a significant increase of mortality suggesting that metabolic resistance mechanisms are contributing to the reduced susceptibility. A negative association was observed between the L1014F-kdr mutation and clothianidin resistance with a greater frequency of homozygote resistant mosquitoes among the dead than among survivors (OR = 0.5; P = 0.02). However, the I114T-GSTe2 was in contrast significantly associated with a greater ability to survive clothianidin with a higher frequency of homozygote resistant among survivors than other genotypes (OR = 2.10; P = 0.013). Conclusions This study revealed a contrasted susceptibility pattern depending on the solvents with ethanol/acetone resulting to lower mortality, thus possibly overestimating resistance, whereas the MERO consistently showed a greater efficacy of neonicotinoids but it could prevent to detect early resistance development. Therefore, we recommend monitoring the susceptibility using both acetone alone and acetone + MERO (4 µg/ml for clothianidin) to capture the accurate resistance profile of the mosquito populations. Graphical Abstract ![]()
Supplementary Information The online version contains supplementary material available at 10.1186/s40249-022-00962-4.
Collapse
|
6
|
Promoting Sustainability through Next-Generation Biologics Drug Development. SUSTAINABILITY 2022. [DOI: 10.3390/su14084401] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The fourth industrial revolution in 2011 aimed to transform the traditional manufacturing processes. As part of this revolution, disruptive innovations in drug development and data science approaches have the potential to optimize CMC (chemistry, manufacture, and control). The real-time simulation of processes using “digital twins” can maximize efficiency while improving sustainability. As part of this review, we investigate how the World Health Organization’s 17 sustainability goals can apply toward next-generation drug development. We analyze the state-of-the-art laboratory leadership, inclusive personnel recruiting, the latest therapy approaches, and intelligent process automation. We also outline how modern data science techniques and machine tools for CMC help to shorten drug development time, reduce failure rates, and minimize resource usage. Finally, we systematically analyze and compare existing approaches to our experiences with the high-throughput laboratory KIWI-biolab at the TU Berlin. We describe a sustainable business model that accelerates scientific innovations and supports global action toward a sustainable future.
Collapse
|
7
|
Ncube BM, Dube A, Ward K. Medicines Regulatory Science Expertise in Africa: Workforce Capacity Development and Harmonisation Activities Towards the Establishment of the African Medicines Agency. Pharmaceut Med 2022; 36:83-97. [DOI: 10.1007/s40290-022-00425-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/22/2022] [Indexed: 12/01/2022]
|
8
|
Wilson JL, Cheung KWK, Lin L, Green EAE, Porrás AI, Zou L, Mukanga D, Akpa PA, Darko DM, Yuan R, Ding S, Johnson WCN, Lee HA, Cooke E, Peck CC, Kern SE, Hartman D, Hayashi Y, Marks PW, Altman RB, Lumpkin MM, Giacomini KM, Blaschke TF. Scientific considerations for global drug development. Sci Transl Med 2021; 12:12/554/eaax2550. [PMID: 32727913 DOI: 10.1126/scitranslmed.aax2550] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Revised: 06/05/2019] [Accepted: 11/05/2019] [Indexed: 12/12/2022]
Abstract
Requiring regional or in-country confirmatory clinical trials before approval of drugs already approved elsewhere delays access to medicines in low- and middle-income countries and raises drug costs. Here, we discuss the scientific and technological advances that may reduce the need for in-country or in-region clinical trials for drugs approved in other countries and limitations of these advances that could necessitate in-region clinical studies.
Collapse
Affiliation(s)
- Jennifer L Wilson
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - Kit Wun Kathy Cheung
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - Lawrence Lin
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - Elizabeth A E Green
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - Analia I Porrás
- Medicines and Health Technologies Unit, Department of Health Systems and Services, Pan American Health Organization, Regional Office of the World Health Organization, Washington, DC, USA
| | - Ling Zou
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - David Mukanga
- Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA
| | - Paul A Akpa
- Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | | | - Rae Yuan
- Sinovant Sciences Co., Shanghai, China
| | - Sheng Ding
- School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.,Gladstone Institute of Cardiovascular Disease, San Francisco, CA, USA
| | | | - Howard A Lee
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.,Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Suwon, Republic of Korea
| | - Emer Cooke
- World Health Organization, Geneva, Switzerland
| | - Carl C Peck
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.,NDA Partners LLC, San Luis Obispo, CA, USA
| | - Steven E Kern
- Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA
| | - Dan Hartman
- Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA
| | | | - Peter W Marks
- Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Russ B Altman
- Departments of Bioengineering and Genetics, Stanford University, Stanford, CA, USA
| | - Murray M Lumpkin
- Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA
| | - Kathleen M Giacomini
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
| | - Terrence F Blaschke
- Departments of Medicine and Molecular Pharmacology, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|
9
|
|
10
|
Research of Epidemic Big Data Based on Improved Deep Convolutional Neural Network. COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE 2020; 2020:3641745. [PMID: 32774444 PMCID: PMC7396034 DOI: 10.1155/2020/3641745] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/23/2020] [Accepted: 06/23/2020] [Indexed: 02/06/2023]
Abstract
In recent years, with the acceleration of the aging process and the aggravation of life pressure, the proportion of chronic epidemics has gradually increased. A large amount of medical data will be generated during the hospitalization of diabetics. It will have important practical significance and social value to discover potential medical laws and valuable information among medical data. In view of this, an improved deep convolutional neural network (“CNN+” for short) algorithm was proposed to predict the changes of diabetes. Firstly, the bagging integrated classification algorithm was used instead of the output layer function of the deep CNN, which can help the improved deep CNN algorithm constructed for the data set of diabetic patients and improve the accuracy of classification. In this way, the “CNN+” algorithm can take the advantages of both the deep CNN and the bagging algorithm. On the one hand, it can extract the potential features of the data set by using the powerful feature extraction ability of deep CNN. On the other hand, the bagging integrated classification algorithm can be used for feature classification, so as to improve the classification accuracy and obtain better disease prediction effect to assist doctors in diagnosis and treatment. Experimental results show that compared with the traditional convolutional neural network and other classification algorithm, the “CNN+” model can get more reliable prediction results.
Collapse
|
11
|
van der Graaf PH. Finding New Drugs for Infectious Diseases: Development Times and Success Rates. Clin Pharmacol Ther 2020; 107:305-307. [PMID: 31960965 DOI: 10.1002/cpt.1728] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Accepted: 11/22/2019] [Indexed: 11/11/2022]
|
12
|
van der Graaf PH, Giacomini KM. Clinical Pharmacology & Therapeutics 2030. Clin Pharmacol Ther 2019; 107:13-16. [PMID: 31863685 DOI: 10.1002/cpt.1705] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Accepted: 10/23/2019] [Indexed: 12/18/2022]
|
13
|
Zineh I, Hartman D. What's Past Is Prologue: Clinical Pharmacology at the Intersection of Science, Policy, and Patients. Clin Pharmacol Ther 2019; 107:33-36. [PMID: 31675100 DOI: 10.1002/cpt.1650] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 09/12/2019] [Indexed: 01/23/2023]
Affiliation(s)
- Issam Zineh
- Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA
| | - Dan Hartman
- Integrated Development, Global Health, Bill and Melinda Gates Foundation, Seattle, Washington, USA
| |
Collapse
|